Cost-Effectiveness of Sorafenib Versus Selective Internal Radiation Therapy for Patients with Advanced Hepatocellular Carcinoma

被引：0
|
作者：
Parikh, Neehar Dilip [1 ]
Singal, Amit G. [2 ]
Kulik, Laura M. [3 ]
Hutton, David [4 ]
机构：
[1] Univ Michigan, Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Internal Med, Dallas, TX 75390 USA
[3] Northwestern Med Fac Fdn, Chicago, IL USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
908
引用
收藏
页码：532A / 533A
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma.
    Gao, X.
    Reddy, P.
    Dhanda, R.
    Gondek, K.
    Yeh, Y. C.
    Stadler, W. M.
    Jonasch, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
  • [42] The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The SORAMIC trial palliative cohort
    Ricke, J.
    Sangro, B.
    Amthauer, H.
    Bargellini, I.
    Bartenstein, P.
    De Toni, E.
    Gasbarrini, A.
    Klumpen, H. J.
    Peck, M.
    Popovic, P.
    Rosmorduc, O.
    Schott, E.
    Verslype, C.
    Malfertheiner, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort
    Ricke, J.
    Sangro, B.
    Amthauer, H.
    Bargellini, I.
    Bartenstein, P.
    De Toni, E.
    Gasbarrini, A.
    Klumpen, H. -J.
    Peck-Radosavljevic, M.
    Popovic, P.
    Rosmorduc, O.
    Schott, E.
    Van Buskirk, M.
    Malfertheiner, P.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S102 - S102
  • [44] SELECTIVE INTERNAL RADIATION THERAPY FOR HEPATOCELLULAR CARCINOMA: COMBINATION WITH SORAFENIB IS ASSOCIATED WITH IMPROVED SURVIVAL OUTCOMES
    Ma, M. X.
    Adams, L.
    Garas, G.
    Macquillan, G.
    O'dea, M.
    Samuelson, S.
    Tibballs, J.
    Mac Nicholas, R.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S211 - S211
  • [45] Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
    Saiyed, Masnoon
    Byrnes, Joshua
    Srivastava, Tushar
    Scuffham, Paul
    Downes, Martin
    CLINICAL DRUG INVESTIGATION, 2020, 40 (12) : 1167 - 1176
  • [46] Downstaging locally advanced hepatocellular carcinoma with selective internal radiation therapy.
    Hoang, Marjorie
    Chow, Pierce K. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 536 - 536
  • [47] Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
    Masnoon Saiyed
    Joshua Byrnes
    Tushar Srivastava
    Paul Scuffham
    Martin Downes
    Clinical Drug Investigation, 2020, 40 : 1167 - 1176
  • [48] First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Choi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S97 - S97
  • [49] First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Chiang, Chi-Leung
    Chan, Sik-Kwan
    Lee, Shing-Fung
    Choi, Horace Cheuk-Wai
    CANCERS, 2021, 13 (05) : 1 - 13
  • [50] Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis
    Shlomai, Amir
    Leshno, Moshe
    Goldstein, Daniel A.
    PLOS ONE, 2018, 13 (11):
12345